Teligene Overview

  • Founded
  • 2011
  • Status
  • Private
  • Employees
  • 11
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $92.7M
Latest Deal Amount
  • Investors
  • 14

Teligene General Information


Developer and researcher of small-molecule drugs intended to improve cancer patient outcomes. The company is dedicated to develop innovative therapeutic approaches in oncology and small-molecule anti-tumor drugs, aiming to provide high-quality research and pharmaceutical products for healthcare practitioners to improve the lives of cancer patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Bio Nano Park, A4-416
  • 218 Xinghu Avenue, Industrial Park District
  • Suzhou, Jiangsu 215123
  • China
+86 0512 0000 0000

Teligene Timeline

Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Teligene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 10-Feb-2021 $92.7M 00000 Completed Clinical Trials - General
5. Later Stage VC (Series C) 17-Aug-2018 000.00 000.00 Completed Clinical Trials - General
4. Later Stage VC 06-Jul-2017 Completed Clinical Trials - General
3. Later Stage VC 01-Jun-2017 Completed Clinical Trials - General
2. Secondary Transaction - Private 23-Aug-2016 Completed Clinical Trials - General
1. Early Stage VC 01-Apr-2012 Completed Clinical Trials - General
To view Teligene’s complete valuation and funding history, request access »

Teligene Executive Team (1)

Name Title Board Seat Contact Info
Xiaoyang Xia Chairman
To view Teligene’s complete executive team members history, request access »

Teligene Board Members (1)

Name Representing Role Since
Xiaoyang Xia Teligene Chairman 000 0000
To view Teligene’s complete board members history, request access »

Teligene Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Teligene Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alan AMC Venture Capital Minority 000 0000 000000 0
Alpha Asset Management China Asset Manager Minority 000 0000 000000 0
China Reform Holdings Corporation Corporation Minority 000 0000 000000 0
CICC Jia Cheng Investment Management Company Venture Capital Minority 000 0000 000000 0
Mirae Asset Asset Manager Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »